{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:09:01Z","timestamp":1794658141683,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.eururo.2015.04.039","type":"journal-article","created":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T23:00:05Z","timestamp":1431730805000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":342,"title":["Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment"],"prefix":"10.1016","volume":"70","author":[{"given":"Scott A.","family":"Tomlins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Lonigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Hovelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Priya","family":"Kunju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney L.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrea","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Groskopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arul M.","family":"Chinnaiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.04.039_bib0155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.04.039_bib0160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ucl.2014.01.002","article-title":"What do the screening trials really tell us and where do we go from here?","volume":"41","author":"Etzioni","year":"2014","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2015.04.039_bib0165","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schroder","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.04.039_bib0170","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.04.039_bib0175","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2217\/fon.09.121","article-title":"Critical review of prostate cancer predictive tools","volume":"5","author":"Shariat","year":"2009","journal-title":"Future Oncol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0180","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.eururo.2011.11.029","article-title":"Risk-based prostate cancer screening","volume":"61","author":"Zhu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ucl.2014.01.003","article-title":"Emerging PSA-based tests to improve screening","volume":"41","author":"Bryant","year":"2014","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2015.04.039_bib0190","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.juro.2010.12.032","article-title":"A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng\/ml prostate specific antigen range","volume":"185","author":"Catalona","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0195","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2009.24.1968","article-title":"Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication","volume":"28","author":"Vickers","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0200","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1756287213495915","article-title":"Biomarkers in prostate cancer surveillance and screening: past, present, and future","volume":"5","author":"Cary","year":"2013","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0205","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.juro.2012.04.143","article-title":"Toward the detection of prostate cancer in urine: a critical analysis","volume":"189","author":"Truong","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0210","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.juro.2011.10.133","article-title":"Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion","volume":"187","author":"Salagierski","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0215","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2011.08.003","article-title":"Contemporary role of prostate cancer antigen 3 in the management of prostate cancer","volume":"60","author":"Auprich","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0220","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1158\/1055-9965.EPI-12-0042","article-title":"The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis","volume":"21","author":"Pettersson","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.eururo.2015.04.039_bib0225","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/modpathol.2013.169","article-title":"Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG","volume":"27","author":"Warrick","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0230","doi-asserted-by":"crossref","first-page":"94ra72","DOI":"10.1126\/scitranslmed.3001970","article-title":"Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA","volume":"3","author":"Tomlins","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2015.04.039_bib0235","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pros.22563","article-title":"Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer","volume":"73","author":"Cornu","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2015.04.039_bib0240","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1373\/clinchem.2012.195560","article-title":"Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based Prostate Health Index for detection of prostate cancer","volume":"59","author":"Stephan","year":"2013","journal-title":"Clin Chem"},{"key":"10.1016\/j.eururo.2015.04.039_bib0245","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1309\/AJCPU7PPWUPYG8OH","article-title":"Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden","volume":"138","author":"Young","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0250","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-12-3283","article-title":"Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study","volume":"19","author":"Lin","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2015.04.039_bib0255","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2013.52.8505","article-title":"Can urinary PCA3 supplement PSA in the early detection of prostate cancer?","volume":"32","author":"Wei","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0260","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.eururo.2015.04.039_bib0265","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2012.07.030","article-title":"Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay","volume":"63","author":"Hansen","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0270","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2012.11.014","article-title":"Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer","volume":"65","author":"Leyten","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0275","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer","volume":"68","author":"Parekh","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0280","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.juro.2015.01.091","article-title":"Multicenter evaluation of the Prostate Health Index for detection of aggressive prostate cancer in biopsy naive men","volume":"194","author":"de la Calle","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0285","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.eururo.2014.06.027","article-title":"TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer","volume":"66","author":"Steurer","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0290","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/pcan.2013.4","article-title":"Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer","volume":"16","author":"Schaefer","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2015.04.039_bib0295","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.juro.2009.10.003","article-title":"Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program","volume":"183","author":"Tosoian","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.04.039_bib0300","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.eururo.2014.02.058","article-title":"ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer","volume":"66","author":"Berg","year":"2014","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815003978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815003978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T01:32:01Z","timestamp":1566696721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283815003978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0302283815003978"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.04.039","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.04.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}